Nymox Pharmaceutical Corp
NYMX
Get informed when a big investor buys or sells
+ FollowMarket Cap$18.24M
Close$
Share Statistics
| Market cap | $18.24 Million |
|---|---|
| Enterprise Value | $18.17 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.07 |
| Beta | 0.82 |
| Outstanding Shares | 91,265,140 |
Return
| Return on Equity | 116.90% |
|---|---|
| Return on Assets | -1211.01% |
| Return on Invested Capital | 113.96% |
Valuation & Multiples
| P/E Ratio | -0.72 |
|---|---|
| PEG | 0.86 |
| Price to Sales | - |
| Price to Book Ratio | -0.2 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -2.35 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Nymox Pharmaceutical Corp
16 employees
CEO: Paul Averback Nymox Pharmaceutical Corporation is a biopharmaceutical firm focused on the research and development of medications for the aging population. Operating internationally, including in Canada, the United States, and Europe, the company's fl...